Chardan analyst Keay Nakae initiated coverage of Korro Bio (KRRO) with a Buy rating and $25 price target Korro is an “intriguing small-cap story” that now trades at a compelling entry point, the analyst tells investors in a research note. The firm cites the potential of the company’s enabling design platform for ADAR RNA base-editing therapeutics for the Buy rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio appoints Loic Vincent as Chief Scientific Officer
- Korro Bio CFO Returns from Medical Leave
- Korro Bio Reports 2024 Financial Results and Progress
- Korro Bio price target lowered to $95 from $105 at RBC Capital
- Korro Bio’s Promising Growth: Buy Rating Backed by Positive KRRO-110 Trial Progress and Market Opportunities